Ensign Peak Advisors
ICPT

Ensign Peak Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ensign Peak Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,070
Closed -$154K – 2296
2022
Q3 		$154K Hold
11,070
– – ﹤0.01% 1967
2022
Q2 		$153K Hold
11,070
– – ﹤0.01% 1875
2022
Q1 		$180K Hold
11,070
– – ﹤0.01% 1901
2021
Q4 		$180K Buy
+11,070
New +$187K ﹤0.01% 1947

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ensign Peak Advisors's ICPT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 11,070 shares — an estimated $154K sold.

Ensign Peak Advisors first reported a position in ICPT in Q4 2021 and held it in 4 quarters. The position peaked at $180K in Q1 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 11,070 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $154K.
  • Ensign Peak Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Intercept Pharmaceuticals, Inc. position peaked at $180K in Q1 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.